Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

被引：12
|
作者：
Trudel, Suzanne [1 ]
McCurdy, Arleigh [2 ]
Fu, Molei [3 ]
Sutherland, Heather J. [4 ]
Louzada, Martha L. [5 ]
Chu, Michael P. [6 ]
White, Darrell J. [7 ,8 ]
Mian, Hira S. [9 ]
Kotb, Rami [10 ]
Othman, Ibraheem [11 ]
Kardjadj, Moustafa [12 ]
Gul, Engin [13 ]
Reece, Donna E. [3 ]
机构：
[1] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[2] Ottawa Hosp, Dept Med, Div Hematol, Ottawa, ON, Canada
[3] Canadian Myeloma Res Grp CMRG, Vaughan, ON, Canada
[4] Vancouver Gen Hosp, Div Hematol, Vancouver, BC, Canada
[5] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada
[6] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada
[7] Dalhousie Univ, Halifax, NS, Canada
[8] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[9] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[10] CancerCare Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, Canada
[11] Saskatchewan Canc Agcy, Allan Blair Canc Ctr, Regina, SK, Canada
[12] Canadian Myeloma Res Grp, Toronto, ON, Canada
[13] Canadian Myeloma Res Grp CMRG, Concord, ON, Canada
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-160445
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7306 / 7307
页数：2
相关论文
共 50 条
  • [21] Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
    Trudel, Suzanne
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Vorobyev, Vladimir
    Hang Quach
    Spicka, Ivan
    Radocha, Jakub
    Robak, Pawel
    Kim, Kihyun
    Cavo, Michele
    Suzuki, Kazuhito
    Morris, Kristin
    Pompilus, Farrah
    Wilkes, Jodie
    Philips-Jones, Amy
    Zhou, Xiaoou
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Mateos Manteca, Maria-Victoria
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S39 - S40
  • [22] Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma
    Hussain, M. Junaid
    Robinson, Myra M.
    Hamadeh, Issam
    Arnall, Justin
    Bhutani, Manisha
    Atrash, Shebli
    Friend, Reed
    Pineda-Roman, Mauricio
    Symanowski, James T.
    Usmani, Saad Z.
    Voorhees, Peter M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) : 140 - 144
  • [23] Pomalidomide in combination with dexamethasone approved for use in refractory multiple myeloma
    Brown, Emily
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2013, 2 (06) : 516 - 517
  • [24] Pomalidomide in combination with dexamethasone approved for use in refractory multiple myeloma
    Brown, Emily
    FUTURE ONCOLOGY, 2013, 9 (11) : 1684 - 1685
  • [25] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
    Condorelli, Annalisa
    Garibaldi, Bruno
    Gagliano, Caterina
    Romano, Alessandra
    Del Fabro, Vittorio
    Parrinello, Nunziatina Laura
    Longo, Antonio
    Cosentino, Sebastiano
    Di Raimondo, Francesco
    Conticello, Concetta
    ACTA HAEMATOLOGICA, 2024, 147 (04) : 493 - 498
  • [26] Belantamab in Combination with Dexamethasone in Patients with TripleClass Relapsed/Refractory Multiple Myeloma
    Atieh, Tahani
    Atrash, Shebli
    Mohan, Meera
    Shune, Leyla
    Mahmoudjafari, Zahra
    Quick, Julie
    Riffel, Justin
    McGuirk, Joseph P.
    Mohyuddin, Ghulam Rehman
    Abdallah, Al-Ola
    Ahmed, Nausheen
    Cui, Wei
    Wishna, Anne
    BLOOD, 2021, 138
  • [27] Belantamab-mafodotin treatment for relapsed or refractory multiple myeloma
    Stocker, Nicolas
    HEMATOLOGIE, 2020, 26 (02): : 99 - 100
  • [28] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
    Condorelli, Annalisa
    Garibaldi, Bruno
    Gagliano, Caterina
    Romano, Alessandra
    Del Fabro, Vittorio
    Parrinello, Nunziatina Laura
    Longo, Antonio
    Cosentino, Sebastiano
    Di Raimondo, Francesco
    Conticello, Concetta
    ACTA HAEMATOLOGICA, 2021,
  • [29] The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
    Becnel, Melody R.
    Lee, Hans C.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [30] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2016, 128 (22)
12345